AI English summary of an SEC filing — figures as filed
Charles River Laboratories CRLThe company said revenue for the 3 months ended March 30, 2024 decreased to $1,011.6 million from $1,029.4 million in the year-earlier period, down 1.7%, and that operating income was $126.0 million (operating margin of 12.5%), compared with $167.9 million (16.3%) a year earlier.
Key points
AI summaryThe company said revenue for the 3 months ended March 30, 2024 decreased to $1,011.6 million from $1,029.4 million in the year-earlier period, down 1.7%, and that operating income was $126.0 million (operating margin of 12.5%), compared with $167.9 million (16.3%) a year earlier.
The company said DSA revenue fell $56.9 million over the 3 months, with the DSA operating margin at 19.0% (25.9% a year earlier), while RMS revenue rose $21.1 million and Manufacturing revenue rose $17.9 million.
The company said it recognized restructuring charges of about $17 million for the 3 months ended March 30, 2024, including $8 million in asset impairment and accelerated depreciation and $9 million in severance. It said the actions already taken and other planned actions are expected to produce annual cost savings of about $70 million.
The company said net cash provided by operating activities for the 3 months was $129.9 million, compared with $109.4 million a year earlier. It also said the carrying value of inventory related to Cambodia-sourced non-human primate shipments was about $27 million as of March 30, 2024.
Key figures
Quarter ended March 30, 2024
- Revenue
- $1.0B
- Operating income
- $126M
- Net income
- $73M
- EPS
- $1.30
- Operating cash flow
- $130M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Q1 2024 Revenue and Operating Income
The company said revenue for the 3 months ended March 30, 2024 decreased to $1,011.6 million from $1,029.4 million in the year-earlier period, down 1.7%, and that operating income was $126.0 million (operating margin of 12.5%), compared with $167.9 million (16.3%) a year earlier.
Source · Based on the MD&A text of the filing
Segment Revenue Changes and DSA Operating Margin
The company said DSA revenue fell $56.9 million over the 3 months, with the DSA operating margin at 19.0% (25.9% a year earlier), while RMS revenue rose $21.1 million and Manufacturing revenue rose $17.9 million.
Source · Based on the MD&A text of the filing
Restructuring Charges and Annual Cost Savings
The company said it recognized restructuring charges of about $17 million for the 3 months ended March 30, 2024, including $8 million in asset impairment and accelerated depreciation and $9 million in severance. It said the actions already taken and other planned actions are expected to produce annual cost savings of about $70 million.
Source · Based on the MD&A text of the filing
Operating Cash Flow and Cambodia Non-Human Primate Inventory
The company said net cash provided by operating activities for the 3 months was $129.9 million, compared with $109.4 million a year earlier. It also said the carrying value of inventory related to Cambodia-sourced non-human primate shipments was about $27 million as of March 30, 2024.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…